

## ***Information for Pharmacists***

# **Claims Submission Procedure – Manitoba Designated Drug Shortages**

***Effective March 09, 2018***

**Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.**

The following DPIN claims submission procedure should be used when Manitoba identifies an active drug shortage.

### **Procedure:**

- A drug shortage is defined as a situation in which an authorization holder for a drug is unable to meet the demand for the drug. Drug shortages can include temporary disruptions or permanent discontinuances in the production and supply of a drug.
- The website for reporting drug shortages and discontinuations in Canada is found at <https://www.drugshortagescanada.ca/>.
- This Procedure applies when Manitoba designates an active drug shortage.

#### **1. Manitoba communicates that “No Generic Manufacturer is able to Supply”:**

- Manitoba will assign a special drug shortage PIN to allow pharmacists to submit the cost of the brand name product. This PIN is specific to the shortage and must be used when submitting a claim. Manitoba will inform pharmacy providers once the shortage has been resolved and the PIN is no longer required and has been withdrawn for coverage.
- After the PIN has been withdrawn by Manitoba, all claims for that PIN will be rejected.

#### **2. Manitoba communicates that “No Manufacturer is Able to Supply”:**

- When extemporaneous drug shortage compounding is required, Manitoba will assign a special compounding PIN. This PIN is specific to the shortage and must be used when submitting a claim. Manitoba will inform pharmacy providers once the shortage has been resolved and compounding is no longer required and has been withdrawn for coverage.
- The Pharmacy Claims Submission Manual (also known as the DPIN Manual) requires that when submitting a claim for an extemporaneous product to Manitoba, the pharmacy must enter the 1) Drug Cost and 2) the Preparation Cost or Professional Fee.

- The **Drug Cost** for an extemporaneous drug shortage compound will be provided in a compound recipe provided to pharmacists by Manitoba. The recipe will outline information specific to each compound, including but not limited to:
  - An itemized list of all extemporaneous product (compound) ingredients and their concentration, dosage form and quantity,
  - The itemized cost of each ingredient and total ingredient costs,
  - The itemized supply and equipment costs and total costs, and
  - The number of minutes required to compound the product.
  
- The **Professional Fee**, for an extemporaneous drug shortage compound, may not exceed *the greater of*:
  - (a) \$30; or the Usual and Customary (U&C) Professional Fee (the amount regularly charged by the pharmacist to persons responsible for paying the professional fee without reimbursement),

OR

  - (b) the Preparation Cost – the amount determined by multiplying the number of minutes specified in the recipe issued by Manitoba spent on the preparation by:
    - (i) \$1 in the case of non-sterile preparation, or
    - (ii) \$2 in the case of a sterile preparation
  
- Manitoba has the authority to audit and recover funds for extemporaneous drug shortage product claims submitted that are inconsistent with these reimbursement procedures and/or any other Manitoba policy.

If your questions are not answered by reviewing the Claims Submission Procedures and  
FAQs posted at:

<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to [PDPIInfoAudit@gov.mb.ca](mailto:PDPIInfoAudit@gov.mb.ca).

## Drug Shortage PIN List to June 24, 2019

### No Generic Manufacturer Is Able to Supply

DRUG	PIN	DATE ISSUED	ACTIVE	DATE DISCONTINUED
Pred-Forte 1%	00911712	June 17, 2019	Y	
Hydromorph Contin 12 mg	00911711	June 10, 2019	Y	
Hyzaar 100/12.5mg	00911710	May 22, 2019	Y	
Cozaar 100mg	00911707	May 19, 2019	Y	
Tri-Cylen LO 21 day	00911708	May 19, 2019	Y	
Zofran ODT 4 mg	00911706	May 1, 2019	Y	
Champix 0.5 mg	00911704	April 25, 2019	Y	
Isoptin SR 120 mg	00911703	April 18, 2019	Y	
Protopic (CMPD)	00911702	April 12, 2019	Y	
Champix - Starter Kit	00911662	March 19, 2019	Y	
Lopressor SR 200 mg	00911701	March 15, 2019	Y	
Concerta 27 mg	00911699	March 11, 2019	Y	
Hydromorph Contin 3 mg	00911698	March 8, 2019	Y	
Chloral Hydrate 100mg/mL	00911700	February 9, 2019	Y	
Cozaar 25 mg	00911691	January 30, 2019	Y	
Cozaar 50 mg	00911692	January 30, 2019	Y	
Zofran ODT 8 mg	00911686	January 24, 2019	Y	
Hydromorph Contin 6 mg	00911687	January 24, 2019	Y	
Hydromorph Contin 9 mg	00911688	January 24, 2019	Y	
Concerta 36 mg	00911683	January 14, 2019	Y	
Accupril 5 mg	00911666	November 12, 2018	Y	
Accupril 10 mg	00911668	November 12, 2018	Y	
Accupril 20 mg	00911670	November 12, 2018	Y	
Accupril 40 mg	00911672	November 12, 2018	Y	
Concerta 54 mg	00911642	August 31, 2018	Y	
Wellbutrin XL 150 mg	00911634	August 1, 2018	Y	
Wellbutrin XL 300 mg	00911636	August 1, 2018	Y	
Dexedrine 15 mg	00911622	December 14, 2018	N	June 10, 2019
Concerta 18 mg	00911682	January 14, 2019	N	June 10, 2019
Tegretol 200 mg	00911696	February 20, 2019	N	June 10, 2019
Tri-Cylen LO 28 day	00911709	May 19, 2019	N	June 10, 2019
Dexedrine 10 mg	00911640	October 15, 2018	N	May 31, 2019
Voltaren SR 100 mg	00911676	December 3, 2018	N	May 31, 2019
Voltaren SR 75 mg	00911684	January 14, 2019	N	May 31, 2019
Restoril 15 mg **	00911689	January 24, 2019	N	May 31, 2019
Restoril 30 mg **	00911690	January 24, 2019	N	May 31, 2019
Sinequan 10mg**	00911693	February 7, 2019	N	May 31, 2019
Sinequan 25mg**	00911694	February 7, 2019	N	May 31, 2019

DRUG	PIN	DATE ISSUED	ACTIVE	DATE DISCONTINUED
Sinequan 50mg**	00911697	February 28, 2019	N	May 31, 2019
Champix 1 mg	00911705	April 25, 2019	N	May 31, 2019
Suboxone 8/2 mg	00911673	April 29, 2019	N	May 20, 2019
Vaseretic 10/25 mg	00911652	September 19, 2018	N	April 15, 2019
Macrobid 100 mg	00911675	December 11, 2018	N	April 15, 2019
Aromasin 25 mg	00911680	January 7, 2019	N	April 15, 2019
Coversyl HD 2.5/8 mg	00911695	February 11, 2019	N	April 15, 2019
Effexor XR 37.5 mg	00911685	January 21, 2019	N	February 21, 2019
Tobi 300mg/15mL	00911604	April 1, 2018	N	February 21, 2019
Sectral 200 mg	00911608	April 27, 2018	N	February 21, 2019
Dostinex 0.5 mg	00911612	April 27, 2018	N	February 21, 2019
Acebutolol 100 mg	00911614	May 3, 2018	N	February 21, 2019
Atripla 6/2/3x100	00911616	May 15, 2018	N	February 21, 2019
Celebrex 100 mg	00911618	June 19, 2018	N	February 21, 2019
Dilantin 100 mg	00911620	July 15, 2018	N	February 21, 2019
Ritalin 20 mg	00911624	July 15, 2018	N	February 21, 2019
Zeldox 40 mg	00911626	July 15, 2018	N	February 21, 2019
Zeldox 20 mg	00911628	July 15, 2018	N	February 21, 2019
Zeldox 60 mg	00911630	July 15, 2018	N	February 21, 2019
Zeldox 80 mg	00911632	July 15, 2018	N	February 21, 2019
Epipen	00911641	August 17, 2018	N	February 21, 2019
AUVI Q	00911644	September 1, 2018	N	February 21, 2019
Acular 0.5%	00911648	September 10, 2018	N	February 21, 2019
Dilantin - Oral Liquid	00911650	September 14, 2018	N	February 21, 2019
Erythromycin Oph Ointment	00911656	September 26, 2018	N	February 21, 2019
Diovan 80 mg	00911658	October 12, 2018	N	February 21, 2019
Tegretol Oral Suspension	00911660	October 25, 2018	N	February 21, 2019
Dexedrine 5 mg	00911664	November 12, 2018	N	February 21, 2019
Arixtra 12.5mg/mL	00911674	December 11, 2018	N	February 21, 2019
Kivexa 600/300 mg	00911677	December 31, 2018	N	February 21, 2019
Effexor XR 150 mg	00911678	January 3, 2019	N	February 21, 2019
Trusopt	00911679	January 7, 2019	N	February 21, 2019
Atropine 1%	00911606	February 2, 2018	N	October 15, 2018
Atropine 1% SL Drop	00911610	April 27, 2018	N	October 15, 2018
Agrylin 0.5 mg	00911646	September 1, 2018	N	October 10, 2018
Nitoman 25 mg	00911602	March 1, 2018	N	May 3, 2018
Diclectin 10/10 mg	00911600	March 9, 2018	N	April 19, 2018

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:

<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to [PDPIInfoAudit@gov.mb.ca](mailto:PDPIInfoAudit@gov.mb.ca).